Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 3/2015

01.03.2015 | Review

Role of miR-155 in drug resistance of breast cancer

verfasst von: Dan-dan Yu, Meng-meng Lv, Wei-xian Chen, Shan-liang Zhong, Xiao-hui Zhang, Lin Chen, Teng-fei Ma, Jin-hai Tang, Jian-hua Zhao

Erschienen in: Tumor Biology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expressions at posttranscriptional level. Growing evidence points to their significant role in the acquisition of drug resistance in cancers. Studies show that miRNAs are often aberrantly expressed in human cancer cells which are associated with tumorigenesis, metastasis, invasiveness, and drug resistance. Breast cancer is the leading cause of cancer-induced death in women. Over the last decades, increasing attention has been paid to the effects of miRNAs on the development of breast cancer drug resistance. Among them, miR-155 takes part in a sequence of bioprocesses that contribute to the development of such drug resistance, including repression of FOXO3a, enhancement of epithelial-to-mesenchymal transition (EMT) and mitogen-activated protein kinase (MAPK) signaling, reduction of RhoA, and affecting the length of telomeres. In this review, we discuss the role of miR-155 in the acquisition of breast cancer drug resistance. This will provide a new way in antiresistance treatment of drug-resistant breast cancer.
Literatur
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Pasquier J, Magal P, Boulange-Lecomte C, Webb G, Le Foll F. Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol Direct. 2011;6:5.CrossRefPubMedPubMedCentral
3.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed
4.
Tang R, Li L, Zhu D, Hou D, Cao T, Gu H. Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res. 2012;22:504–15.CrossRefPubMed
5.
Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics. 2011;2:171–85.CrossRefPubMedPubMedCentral
6.
Teng G, Papavasiliou FN. Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci. 2009;364:631–7.CrossRefPubMed
7.
Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014;9:e96228.CrossRefPubMedPubMedCentral
8.
Cui X, Guo Y, Yao H. Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28:1813–5.PubMed
9.
Clurman BE, Hayward WS. Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas: evidence for stage-specific events. Mol Cell Biol. 1989;9:2657–64.CrossRefPubMedPubMedCentral
10.
Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, et al. MiR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Proc Natl Acad Sci U S A. 2012;109:20047–52.CrossRefPubMedPubMedCentral
11.
Zeng H, Fang C, Nam S, Cai Q, Long X. The clinicopathological significance of MicroRNA-155 in breast cancer: a meta-analysis. Biomed Res Int. 2014;2014:1–7.
12.
Zhang JLQM. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res. 2013;25:46–54.PubMedPubMedCentral
13.
Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomark. 2012;21:1236–43.CrossRef
14.
Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene. 2013;32:2992–3000.CrossRefPubMed
15.
Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor /Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28:6773–84.CrossRefPubMedPubMedCentral
16.
Johansson J, Berg T, Kurzejamska E. MiR-155-mediated loss of C/EBPb shifts the TGF-b response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013:5614–5624.
17.
Martin EC, Krebs AE, Burks HE, Elliott S, Baddoo M, Collins-Burow BM, et al. MiR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling. Genes Cancer. 2014;5:353–64.PubMedPubMedCentral
18.
Shu-Rong Zheng GGQZ. Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors. Asian Pac J Cancer Prev. 2013;4:2361–6.CrossRef
19.
20.
21.
22.
Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola DCJ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285:17869–79.CrossRefPubMedPubMedCentral
23.
Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang HT, et al. MicroRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep. 2013;30:2111–8.PubMed
24.
Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol. 2000;20:9138–48.CrossRefPubMedPubMedCentral
25.
Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, et al. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. Cell Signal. 2014;26:1021–9.CrossRefPubMed
26.
Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res. 2004;6:R601–7.CrossRefPubMedPubMedCentral
27.
Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, et al. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2014;33:3422–31.CrossRefPubMed
28.
Liam O, Connor AS, Lorraine A, O Reilly GH, Jerry M, Adams SCA, Huang DCS. Bim bang in cell death O’Connor L, Strasser A, O’Reilly A et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis EMBO J. 17, 384–395. Immunology Today 1998;19:99.
29.
Sonenshein SGAG. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol. 2004;24:8681–90.CrossRefPubMedPubMedCentral
30.
Shaocong Guo YLQT. DEF1 down-regulates ER—a expression and confers tamoxifen resistance in breast cancer. PLoS ONE. 2012;12:e52380.
31.
Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, Dent AL, et al. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem. 2002;277:14255–65.CrossRefPubMed
32.
Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC, et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem. 2004;279:1513–25.CrossRefPubMed
33.
Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ, DiStefano PS, et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science. 2002;296:530–4.CrossRefPubMed
34.
Park S, Guo J, Kim D, Cheng JQ. Identification of 24p3 as a direct target of Foxo3a regulated by interleukin-3 through the phosphoinositide 3-kinase/Akt pathway. J Biol Chem. 2009;284:2187–93.CrossRefPubMedPubMedCentral
35.
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128:309–23.CrossRefPubMedPubMedCentral
36.
37.
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.CrossRefPubMed
38.
39.
Johansson J, Berg T, Kurzejamska E. MiR-155-mediated loss of C/EBPb shifts the TGF-b response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer 2013; 5614–5624.
40.
Wang J, Wu J. Role of miR-155 in breast cancer. Front Biosci (Landmark Ed). 2012;17:2350–5.CrossRef
41.
Qu H, Fang L, Duan L, Long X. Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition. Zhonghua Bing Li Xue Za Zhi. 2014;43:236–40.PubMed
42.
Li W, Liu C, Wang H. Highexpression of Snail leads to the P-gp modulateds MDR in breast cancer cell MCF-7. Chin Pharmacol Bull. 2010:87–90.
43.
Tang Y, Wang H, Chen W. Epithelial-mesenchymal transition modulates P-glucoprotein-induced multidrug resistance in breast cancer MCF-7 cells via p38-MAPK. China J Cancer Biother. 2010;2:144–8.
44.
Zhou GLYL. Reduced BMP6 expression by DNA methylation contributes to EMT and drug resistance in breast cancer cells. Oncol Rep. 2014;2:581–8.
45.
Settleman ASAJ. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;34:4741–51.
46.
Sarkar FH, YLZW. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009;5:489–500.
47.
Neel DS, Bivona TG. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res. 2013;19:3–5.CrossRefPubMed
48.
Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metast Rev. 2009;28:65–76.CrossRef
49.
Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D, et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci. 2014;111:E384–93.CrossRefPubMed
50.
51.
Weber M, Kim S, Patterson N, Rooney K, Searles CD. MiRNA-155 targets myosin light chain kinase and modulates actin cytoskeleton organization in endothelial cells. Am J Physiol Heart Circ Physiol. 2014;306:H1192–203.CrossRefPubMedPubMedCentral
52.
Dagan LN, Jiang X, Bhatt S, Cubedo E, Rajewsky K, Lossos IS. MiR-155 regulates HGAL expression and increases lymphoma cell motility. Blood. 2012;119:513–20.CrossRefPubMedPubMedCentral
53.
Shi JS, Zhang J, Li J. Role of miR-155 in pathogenesis of diffuse large B cell lymphoma and its possible mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:869–72.PubMed
54.
Zhang B, Zhang Y, Dagher MC, Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005;65:6054–62.CrossRefPubMed
55.
Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, et al. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells. 2003;21:315–21.CrossRefPubMed
56.
Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, et al. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res. 2008;6:1607–20.CrossRefPubMed
57.
Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther. 2007;6:1774–84.CrossRefPubMed
58.
Nakagami H, Pitzschke A, Hirt H. Emerging MAP kinase pathways in plant stress signalling. Trends Plant Sci. 2005;10:339–46.CrossRefPubMed
59.
60.
Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92:689–737.CrossRefPubMed
61.
Hommes DW, Peppelenbosch MP, van Deventer SJH. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 2003;52:144–51.CrossRefPubMedPubMedCentral
62.
Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One. 2012;7:e46551.CrossRefPubMedPubMedCentral
63.
Rahadiani N, Takakuwa T, Tresnasari K, Morii E, Aozasa K. Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun. 2008;377:579–83.CrossRefPubMed
64.
Donnelly SM, Paplomata E, Peake BM, Sanabria E, Chen Z, Nahta R. P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. Curr Med Chem. 2014;21:501–10.CrossRefPubMedPubMedCentral
65.
Mei MXDZY. A new 2a,5a,10b,14b-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells. Plos One. 2014;8:e104317.CrossRef
66.
Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2001;276:40888–95.CrossRefPubMed
67.
Heckler MM, HTCC. ERK/MAPK regulates ERRc expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. FEBS J. 2014; 22442–24341.
68.
Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor Gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat. 2008;112:25–33.CrossRefPubMed
69.
Nathan Corbett M, Martin Alda M. On telomeres long and short. J Psychiatry Neurosci. 2015;1:3–4.CrossRef
70.
71.
Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, et al. MiR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res. 2014;74:4145–56.CrossRefPubMed
72.
Cerone MA. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther. 2006;5:1669–75.CrossRefPubMed
73.
Ward RJ. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol. 2005.
74.
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. 2011;13:R56.CrossRefPubMedPubMedCentral
75.
Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1236–43.CrossRefPubMed
76.
Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, et al. Oncogenic microRNAs: MiR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014;14:448.CrossRefPubMedPubMedCentral
Metadaten
Titel
Role of miR-155 in drug resistance of breast cancer
verfasst von
Dan-dan Yu
Meng-meng Lv
Wei-xian Chen
Shan-liang Zhong
Xiao-hui Zhang
Lin Chen
Teng-fei Ma
Jin-hai Tang
Jian-hua Zhao
Publikationsdatum
01.03.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3263-z

Weitere Artikel der Ausgabe 3/2015

Tumor Biology 3/2015 Zur Ausgabe

Research Article

Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast

Research Article

A high level of circulating HOTAIR is associated with progression and poor prognosis of cervical cancer

Research Article

Runx2, a target gene for activating transcription factor-3 in human breast cancer cells

Research Article

Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients

Research Commentary

Comments on Liu Y et al. “Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies”

Research Article

ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise